BioNTech SE

Approval AI-extracted

trastuzumab pamirtecan

endometrial cancer

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on trastuzumab pamirtecan for endometrial cancer is expected Date TBD.

Primary source · SEC 6-K verified 12h ago

“BioNTech and DualityBio plan to file a biologics license application (“BLA”) in 2026, subject to regulatory feedback from the FDA.”